VCP-Eribulin
VCP-Eribulin is a bioactive molecule-linker conjugate designed for ADCs (Drug-Linker Conjugates for ADC), formed by conjugating an ADC linker (VCP) with Eribulin (HY-13442). Eribulin is a unique microtubule inhibitor exhibiting antitumor activity. VCP-Eribulin can be utilized for antibody conjugation.
For research use only. We do not sell to patients.
- CAS No.: 2130869-17-7
- Formula: C59H86N6O16
- Molecular Weight:1135.34
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All Drug-Linker Conjugates for ADC Isoforms
More
Biological Activity
Description
IC50 & Target
|
Traditional Cytotoxic Agents |
In Vitro
VCP-Eribulin is formed by conjugating an ADC linker (VCP) with Eribulin (HY-13442); Eribulin is a unique microtubule inhibitor exhibiting anti-tumor activity. VCP-Eribulin can be utilized for antibody conjugation[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 2130869-17-7
-
Molecular Weight 1135.34
-
Formula C59H86N6O16
-
SMILES
C=C1C[C@@]2([H])O[C@@]1([H])CC[C@]3([H])O[C@](C([C@H](C)C3)=C)([H])C[C@@]4([H])[C@]([C@@H](OC)[C@@H](C[C@H](O)CNC(OCC5=CC=C(NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)N)=O)=O)C=C5)=O)O4)([H])CC(C[C@]6([H])O[C@]7([H])[C@]8([H])O[C@@]9(O[C@@]%10([H])[C@@](O[C@]8([H])[C@@]%10([H])O[C@@]7([H])CC6)([H])C9)CC2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
[1]. Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. US20170252458A1.
[2]. Towle MJ, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011 Jan 15;71(2):496-505. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
VCP-Eribulin Related Classifications
HY-128871 Related Classifications
Powered by Bioz